Comparing the current results to its competitors, Gt Biopharma Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 13.55 %, recorded in the same quarter.
Gt Biopharma Inc , slower than the average decrease reported by the company's competitors of -52.86 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -52.86 %
Gt Biopharma Inc 's Comment on Competition and Industry Peers
The market for therapeutic immuno-oncology products is highly competitive, involving pharmaceutical, biopharmaceutical, and biotechnology companies, as well as academic and research institutions and governmental agencies in the United States and internationally. Competitors are developing drugs and therapies targeting similar diseases and conditions. Additionally, companies researching and developing cell therapies, many with greater financial resources and more experience in testing, regulatory approvals, marketing, and sales, contribute to the competitive landscape. Mergers and acquisitions within the pharmaceutical and biotechnology industries may further concentrate resources among competitors, potentially intensifying competition.
Atea Pharmaceuticals Inc. is a biopharmaceutical company that focuses on developing antiviral therapeutics to combat infectious diseases. Their business model revolves around identifying and advancing novel drug candidates that target specific viral mechanisms and inhibit their replication. This includes conducting preclinical and clinical trials, engaging in strategic partnerships, and ultimately bringing effective antiviral treatments to market.
Incyte Corporation is a biopharmaceutical company that primarily focuses on the research, development, and commercialization of innovative medicines targeting oncology and serious inflammatory conditions. Their business model emphasizes robust R&D investments to discover potential drug candidates, often engaging in collaborations with other organizations to enhance their development capabilities. Incyte leverages its extensive intellectual property portfolio to protect and maximize the value of its therapeutic advancements in the market.
Iterum Therapeutics Plc is a pharmaceutical company that focuses on the research, development, and commercialization of innovative anti-infectives for the treatment of serious and life-threatening infections. They aim to address unmet medical needs in this space by advancing their product candidates through clinical trials and ultimately bringing them to market.
Johnson & Johnson operates as a multinational healthcare company with a diversified business model that spans pharmaceuticals, medical devices, and consumer health products. By focusing on innovation and strategic acquisitions, the company aims to improve global health and well-being.
Sources:
Gt Biopharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Gt Biopharma Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
